Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 0% of the time (33 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-10-13. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: kidneyadmissionscreeninginsulinintravenous
  Phrases that lowered it: progressionclinical trialtimesphase iipatients with
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Maximum age: 99 (lowers risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Responsible party: principal investigator (lowers risk) · Design
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 6.7% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 4 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 63.6% (lowers risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 10 (raises risk) · Sponsor's track record
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports before start: 257021 (raises risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 28851 (raises risk) · Drug's FDA history
• Disease area, respiratory: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI) NCT04344184 · started 2020 · scored riskier than 88% of active trials completed
• Lessening Organ Dysfunction With VITamin C - COVID-19 NCT04401150 · started 2020 · scored riskier than 23% of active trials completed
• COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial) NCT04344041 · started 2020 · scored riskier than 49% of active trials completed
• Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) NCT04478071 · started 2020 · scored riskier than 92% of active trials completed
• Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia NCT04264533 · started 2020 · scored riskier than 44% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.